Megan E.B. Clowse, MD: The structure of certolizumab makes it somewhat different in pregnancy compared with the other TNF inhibitors. The other TNF inhibitors are based on an antibody. They basically have the full human antibody structure. They have a specific part of that antibody called the Fc [fragment crystallizable] portion, and that Fc portion is actually what is grabbed at the placenta and makes the drug drag across the placenta into the baby. So it’s that Fc portion that is really key to transferring the drug from the mother to the infant during pregnancy.
For certolizumab, the structure is different. It does not have an Fc portion. Instead, it has this big kind of globular molecule, and so it can’t be grabbed and pulled across the placenta. Therefore, when we look at babies whose mothers have been treated with TNF inhibitors during pregnancy, when we look at adalimumab-exposed or infliximab-exposed infants, we see that there is actually a pretty high level of drug in the baby compared with the mother. In fact, the baby generally has a higher concentration of the drug on the day of delivery compared with the mom.
Certolizumab, on the other hand, doesn’t move across the placenta because it’s a different molecule. If you check the baby’s level on the day of delivery, the level is either 0 or is very close to 0 and is much lower than what it is in the mother. Because of that, we use the medication in the second half of pregnancy a bit differently. I’m comfortable with patients taking certolizumab through delivery. I often actually have them skip taking it during the week of delivery because of infection risk, but it won’t harm their baby if they take the drug throughout delivery and keep taking it through lactation and breast-feeding.
However, I generally stop treating patients with the other TNF inhibitors about 2 months or so before delivery. The reason for that is because it takes time for the drug to get out of the mother’s system. By doing this, it also allows time for the drug to get out of the baby’s system. When the baby is born, he or she might have a smidgen of the drug in their system, but the level would be low enough that we wouldn’t really worry about the risk for infection.
There is not really a clear guideline as to exactly when to stop each of those medications. I personally pick somewhere between 30 and 34 weeks for most of them. I also negotiate that a little with the woman based on how her arthritis is doing. If she’s really having a lot of trouble with her arthritis, I might continue it a little longer. If she’s doing fantastic, I might stop it a bit sooner. But then in those patients for whom I’ve stopped the drug, it’s key to restart it right after delivery. For women who are on TNF inhibitors before and during pregnancy, if they don’t start back up with a TNF inhibitor after delivery, they will most likely flare, and so I start people back on the drug 1 or 2 weeks after delivery. They can take it during breast-feeding without difficulty. That really avoids the postpartum flare quite effectively.
Patients With HFrEF, HFpEF See Different Functional Capacity Benefits With Dapagliflozin
December 7th 2023The DETERMINE-Reduced and DETERMINE-Preserved trials demonstrated varying benefits of dapagliflozin on Kansas City Cardiomyopathy Questionnaire Total Symptom Score and Physical Limitation Scale as well as 6-minute walk distance.
Read More
Black Patients With Ulcerative Colitis Less Likely to Undergo IPAA Than White Patients
December 7th 2023Overall, the number of patients discharged from hospitals with an ulcerative colitis diagnosis increased between 2009 and 2018, but the number of patients opting for ileal pouch–anal anastomosis (IPAA) decreased.
Read More
Understanding the Unmet Need for Therapies to Treat Rare Bile Duct Cancer
May 24th 2022On this episode of Managed Care Cast, we bring you an excerpt of an interview with a co-chair of the 2022 Cholangiocarcinoma Foundation (CCF) annual conference, held earlier this year, about the significant unmet therapy needs facing most patients with this rare cancer.
Listen
Negotiations to extend US global HIV/AIDS relief work are deadlocked; the Biden administration delayed its rule on the proposed menthol cigarette ban until March 2024 after lobbying by civil rights groups; federal agencies have partnered with a digital health company to create an at-home test-to-treat program for flu and COVID-19.
Read More
New Investigation Analyzes Magnetic Resonance Measures of DMD for Disease Progression
December 7th 2023Investigators evaluated longitudinal MRI and spectroscopy outcomes and ambulatory function among 180 patients with Duchenne muscular dystrophy (DMD) to establish the utility and reproducibility of magnetic resonance measures of muscle quality at different disease stages.
Read More